Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluticasone Furoate

FDA-approved product (spray, metered, nasal), marketed as Arnuity Ellipta, Flonase Sensimist Allergy Relief.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fluticasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic obstructive pulmonary disease
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluticasone Furoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluticasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

    NCT01131806 · start 2009-12

    Registered record
    Registry ID
    NCT01131806
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    fluticasone/ salmeterol 125/25 mcg/puff; fluticasone/ salmeterol 250/25 mcg/puff
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-12
    Completion
    2011-04
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    Interventionfluticasone/ salmeterol 125/25 mcg/puff; fluticasone/ salmeterol 250/25 mcg/puff
    PhasePhase 4
    Registry statusUnknown

  • Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

    NCT01007721 · start 2009-10

    Registered record
    Registry ID
    NCT01007721
    Conditions
    Rhinitis, Allergic, Seasonal; Asthma
    Interventions
    BI 67100 ED 25 mg; BI 671800 ED placebo; montelukast placebo tablet; montelukast placebo tablet; fluticasone propionate placebo nasal spray; fluticasone propionate placebo nasal spray; fluticasone propionate placebo nasal spray; BI 671800 ED 100 mg; BI 671800 ED placebo; BI 671800 ED placebo; BI 671800 ED placebo; BI 671800 ED 100 mg; 671800 ED placebo; montelukast placebo tablet; montelukast placebo tablet; montelukast placebo tablet; montelukast 10 mg tablet; fluticasone propionate placebo nasal spray; fluticasone propionate nasal spray placebo; Fluticasonepropionate nasal spray 200 mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    Not recorded
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Seasonal; Asthma
    InterventionBI 67100 ED 25 mg; BI 671800 ED placebo; montelukast placebo tablet; montelukast placebo tablet +16 more
    PhasePhase 2
    Registry statusCompleted

  • Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo

    NCT01246921 · start 2009-09

    Registered record
    Registry ID
    NCT01246921
    Conditions
    Patients With Active Non-segmental Vitiligo.; Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%; Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
    Interventions
    Fluticasone proprionate 0.05% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-09
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Active Non-segmental Vitiligo.; Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%; Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
    InterventionFluticasone proprionate 0.05% cream
    PhasePhase 4
    Registry statusUnknown

  • Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

    NCT00731770 · start 2009-01

    Registered record
    Registry ID
    NCT00731770
    Conditions
    COPD
    Interventions
    Advair 250; Placebo- matched; Placebo; Advair 250 - matched
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD
    InterventionAdvair 250; Placebo- matched; Placebo; Advair 250 - matched
    PhasePhase 4
    Registry statusCompleted

  • Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma

    NCT00829257 · start 2009-01

    Registered record
    Registry ID
    NCT00829257
    Conditions
    Asthma
    Interventions
    HFA-BDP; Fluticasone; Seretide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-07
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionHFA-BDP; Fluticasone; Seretide
    PhasePhase 4
    Registry statusCompleted

  • Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

    NCT00791973 · start 2008-11

    Registered record
    Registry ID
    NCT00791973
    Conditions
    Allergic Rhinitis
    Interventions
    fluticasone furoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    Interventionfluticasone furoate; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

    NCT00570492 · start 2007-11-26

    Registered record
    Registry ID
    NCT00570492
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Fluticasone furoate nasal spray; Placebo nasal spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-11-26
    Completion
    2011-03-17
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionFluticasone furoate nasal spray; Placebo nasal spray
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

    NCT00562159 · start 2007-11

    Registered record
    Registry ID
    NCT00562159
    Conditions
    Rhinoconjunctivitis; Rhinitis; Conjunctivitis; Allergy
    Interventions
    Placebo; SCH 697243; Loratadine 10 mg Rescue Treatment; Olopatadine 0.1% Rescue Treatment; Mometasone 50 mcg Rescue Treatment; Prednisone 5 mg Rescue Treatment; Albuterol sulfate 108 mcg; Fluticasone propionate 44 mcg; Prednisone 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-11
    Completion
    2009-09
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinoconjunctivitis; Rhinitis; Conjunctivitis; Allergy
    InterventionPlacebo; SCH 697243; Loratadine 10 mg Rescue Treatment; Olopatadine 0.1% Rescue Treatment +5 more
    PhasePhase 3
    Registry statusCompleted

  • Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?

    NCT00509197 · start 2007-10

    Registered record
    Registry ID
    NCT00509197
    Conditions
    Asthma
    Interventions
    Placebo (sham inhaler); Fluticasone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2010-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionPlacebo (sham inhaler); Fluticasone
    PhaseNot applicable
    Registry statusTerminated

  • A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

    NCT00452348 · start 2007-05

    Registered record
    Registry ID
    NCT00452348
    Conditions
    Asthma
    Interventions
    Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID; Fluticasone propionate 250 mcg BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-04
    Enrolment
    628

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone Propionate/salmeterol xinofoate 250/50 mcg BID; Fluticasone propionate 250 mcg BID
    PhasePhase 4
    Registry statusCompleted

  • Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data

    NCT00363480 · start 2006-05-17

    Registered record
    Registry ID
    NCT00363480
    Conditions
    Asthma
    Interventions
    Salmeterol/Fluticasone 50/250 mcg; Salbutamol 100 mcg; DISKUS™ powder inhalers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-05-17
    Completion
    2007-09-14
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionSalmeterol/Fluticasone 50/250 mcg; Salbutamol 100 mcg; DISKUS™ powder inhalers
    PhasePhase 4
    Registry statusCompleted

  • Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

    NCT00353873 · start 2005-11-18

    Registered record
    Registry ID
    NCT00353873
    Conditions
    Asthma
    Interventions
    Fluticasone propionate; Fluticasone propionate/salmeterol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-11-18
    Completion
    2006-10-26
    Enrolment
    506

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionFluticasone propionate; Fluticasone propionate/salmeterol
    PhasePhase 4
    Registry statusCompleted

  • Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

    NCT00235053 · start 2005-08

    Registered record
    Registry ID
    NCT00235053
    Conditions
    Asthma; Candidiasis, Oral; Voice Disorders
    Interventions
    fluticasone/salmeterol DISKUS 250/50
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-08
    Completion
    2005-11
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Candidiasis, Oral; Voice Disorders
    Interventionfluticasone/salmeterol DISKUS 250/50
    PhasePhase 4
    Registry statusCompleted

  • The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

    NCT00119015 · start 2005-07

    Registered record
    Registry ID
    NCT00119015
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Placebo; Montelukast; Fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2005-07
    Completion
    2009-01
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionPlacebo; Montelukast; Fluticasone propionate
    PhasePhase 4
    Registry statusTerminated

  • Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)

    NCT00163423 · start 2004-11

    Registered record
    Registry ID
    NCT00163423
    Conditions
    Asthma
    Interventions
    Ciclesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11
    Completion
    2006-01
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionCiclesonide
    PhasePhase 3
    Registry statusCompleted